Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
John B. Buse(University of North Carolina Health Care), Julio Rosenstock(Dallas Diabetes Research Center), Giorgio Sesti(Magna Graecia University), Wolfgang E. Schmidt(St. Josef-Hospital), Eduard Montanya(Institut d'Investigació Biomédica de Bellvitge), Jason Brett(Novo Nordisk (United States)), Marcin Zychma(Novo Nordisk (Denmark)), Lawrence Blonde(Ochsner Medical Center)
Cited by 1,488
Abstract
Related Papers
No related papers found
Powered by citation graph analysis